Psychedelic research Archives - Medical Design Sourcing

[Image courtesy of Adobe Stock]

With promising interim phase 2 data in hand, Cybin believes psychedelic therapy will become a reality in the “not too distant future,” according to CEO Doug Drysdale.

As recently as the 1990s, it would be difficult to imagine that a psychedelic drug would potentially be a clinical option for a mood disorder like depression. But before long, data from multiple phase 3 trials will be available on psilocybin derivatives for various mood disorders.

Interim phase 2 CYB003 data as a ray of hope for treating mood disorders

Toronto, Canada–based Cybin recently unveiled upbeat interim phase 2 data related to CYB003, a proprietary deuterated psilocybin analog, in patients with moderate to severe major depressive disorder (MDD). In the randomized double-blind placebo-controlled study, CYB003 demonstrated a rapid and robust reduction in depression symptoms just three weeks …

Doors of perception: Psychedelic renaissance or Pandora’s box?

[Knatter Knarz/Adobe Stock]

In one sense, psychedelics have always been divisive in mainstream Western culture. During their heyday in the 1960s, proponents lauded psychedelics’ virtues for psychological healing and exploration. But troubling reports also emerged — stories of bad trips, psychological breaks and mostly apocryphal yet sensationalized reports of individuals leaping from buildings while under the influence. This darker side, combined with Nixon’s targeting of drugs popular with hippies, cast a pall over psychedelic research for decades, making the prospect of FDA approval seem like a practical impossibility.

Psychdelic resurgence and pursuit of FDA approval

But now, thanks to loosening restrictions, psychedelics are as hip as they have been in decades, and are a popular research subject in many academic circles. In June, FDA released gui…

Psychedelic research

Cybin sees near future for psychedelic therapy after promising interim phase 2 data

Aiming to tame psychedelics’ wild side in pursuit of FDA approval